Post by BioThrust

4,932 followers

šŸ“ŗ š— š—¶š˜€š˜€š—²š—± š—¼š˜‚š—æ š—¶š—£š—¦š—– š˜„š—²š—Æš—¶š—»š—®š—æ? š—¬š—¼š˜‚ š—°š—®š—» š—»š—¼š˜„ š˜„š—®š˜š—°š—µ š˜š—µš—² š—³š˜‚š—¹š—¹ š—æš—²š—°š—¼š—æš—±š—¶š—»š—“. In this session, Patrick Bongartz and Marco Oliveira introduce BioThrust, explain the scientific principles of our ComfyCell bioreactor technology, and present a detailed review of our record-setting iPSC expansion proof-of-concept experiments. š—§š—²š—°š—µš—»š—¶š—°š—®š—¹ š—¦š˜‚š—ŗš—ŗš—®š—æš˜†:  • Up to 10x the gas transfer (O2 in, CO2 out) of other bioreactors  • No deadzones in the bioreactor, smooth and homogeneous flow  • Flexible design, compatible with a wide range of analytics and perfusion š—•š—¶š—¼š—¹š—¼š—“š—¶š—°š—®š—¹ š—¦š˜‚š—ŗš—ŗš—®š—æš˜†:  • Removed all gas transfer limits from fed-batch iPSC expansion - now purely nutrient limited  • World record iPSC expansion at 300mL and scale up to 2L: Up to 44 million iPSCs per mL  • Controlled aggregate sizes and full pluripotency maintained A big thank you to everyone who joined our European and US sessions. We were genuinely impressed by the level of interest in this first webinar series. It highlights a shared reality across the field: efficient iPSC manufacturing remains an unsolved challenge, and the need for scalable, commercially viable solutions is more urgent than ever to advance cell therapies and improve patient outcomes. šŸ’™ šŸ‘‰ š—Ŗš—®š˜š—°š—µ š˜š—µš—² š—æš—²š—°š—¼š—æš—±š—¶š—»š—“ š—µš—²š—æš—²: https://lnkd.in/e2xaJAbz

Post content